Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Gracell Reports Positive Data from Trial of BCMA/CD19 FasTCAR-T in Multiple Myeloma

publication date: Jun 5, 2023

Shanghai Gracell Biotech reported its dual-targeting BCMA/CD19 FasTCAR-T candidate showed efficacy in heavily pre-treated patients with relapsed/refractory multiple myeloma. The median duration of response was 37 months in patients who had previously received a median of five therapy rounds, and the median progression free survival was 38 months. FasTCAR-T, Gracell’s CAR-T technology, produces an autologous CAR-T treatment overnight instead of nearly a month. The single-arm, investigator-initiated trial enrolled 29 RRMM patients. Gracell released the data for GC012F, its lead candidate, in an abstract at the ASCO meeting. More details....

Stock Symbol: (NSDQ: GRCL)

Share this with colleagues: